risperidone has been researched along with Diabetes Mellitus in 40 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 7.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| "To compare the incidence rates of diabetes mellitus and dyslipidemia in ambulatory first-time users of risperidone and olanzapine." | 7.73 | Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. ( Cooper, D; Gaudet, M; Grégoire, JP; Moisan, J, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 7.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Pharmacovigilance survey of spontaneously reported adverse events in risperidone-treated patients, with reports of haloperidol-associated hyperglycemia used as a control." | 7.72 | Risperidone-associated diabetes mellitus: a pharmacovigilance study. ( Cross, JT; Doraiswamy, PM; Koller, EA; Schneider, BS, 2003) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 7.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 7.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| "During the last few years, several case reports and studies have been published on the potential diabetes mellitus (DM)-inducing effect of some atypical antipsychotics, especially clozapine and olanzapine." | 4.82 | Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. ( Cohen, D, 2004) |
| "Patients with schizophrenia receive medication to alleviate various symptoms, but some efficacious second generation antipsychotics, particularly olanzapine, can cause obesity, dyslipidemia, and diabetes mellitus." | 3.79 | The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation. ( Harding, H; Mori, K; Nadanaka, S; Nagamine, T; Okada, T; Ozasa, R; Ron, D; Zyryanova, A, 2013) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 3.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| "A 27-year-old man, who has been using risperidone for two months as the treatment for schizophrenia, with no previous history of diabetes was admitted to the hospital with the presentation of severe diabetes ketoacidosis and subsequent fatal progression." | 3.75 | Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient. ( Lu, CH; Yan, YH, 2009) |
| "To compare the incidence rates of diabetes mellitus and dyslipidemia in ambulatory first-time users of risperidone and olanzapine." | 3.73 | Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. ( Cooper, D; Gaudet, M; Grégoire, JP; Moisan, J, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 3.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Atypical antipsychotics, especially clozapine and olanzapine, have been increasingly associated with weight gain and other adverse metabolic events (diabetes mellitus, hyperlipidemia) in non-mentally retarded populations." | 3.73 | Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. ( Ball, MP; Bodfish, JW; Heeth, WL; Mahorney, SL; McKee, JR, 2005) |
| "The risk of the appearance of diabetes mellitus in patients treated with olanzapine is twice as high as that in patients treated with risperidone, and the risk in patients treated with clozapine is nearly triple as high as that found in patients treated with risperidone." | 3.73 | [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study]. ( Burón, JA; Gómez-de-la-Cámara, A; Ledesma, F; Martínez-Junquera, G; Rodríguez-Morales, A; Rubio, G, 2006) |
| "Pharmacovigilance survey of spontaneously reported adverse events in risperidone-treated patients, with reports of haloperidol-associated hyperglycemia used as a control." | 3.72 | Risperidone-associated diabetes mellitus: a pharmacovigilance study. ( Cross, JT; Doraiswamy, PM; Koller, EA; Schneider, BS, 2003) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 3.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "Although clozapine and olanzapine have greater diabetes risk, the attributable risk of diabetes mellitus with atypical antipsychotics is small." | 3.72 | Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. ( Leslie, DL; Rosenheck, RA, 2004) |
| "Exposure to multiple second-generation antipsychotics or clozapine or quetiapine significantly increased the risk of treatment-emergent diabetes mellitus." | 3.72 | Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. ( Allingham, B; Citrome, L; Jaffe, A; Levine, J; Robinson, J, 2004) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 3.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| "To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs." | 3.71 | Glucose intolerance with atypical antipsychotics. ( Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M, 2002) |
| "Two retrospective cases are described in which patients with schizophrenia developed diabetes while taking the antipsychotic medication risperidone." | 3.71 | Risperidone-associated new-onset diabetes. ( Eyeler, J; Pierre, JM; Weinbach, J; Wirshing, DA; Wirshing, WC, 2001) |
| " However, there are still significant adverse effects and toxicities with this class of medications." | 2.43 | Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? ( Dubois, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (85.00) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, D | 1 |
| Uda, K | 1 |
| Kumazawa, R | 1 |
| Matsui, H | 1 |
| Yasunaga, H | 1 |
| Ninagawa, S | 1 |
| Tada, S | 1 |
| Okumura, M | 1 |
| Inoguchi, K | 1 |
| Kinoshita, M | 1 |
| Kanemura, S | 1 |
| Imami, K | 1 |
| Umezawa, H | 1 |
| Ishikawa, T | 1 |
| Mackin, RB | 1 |
| Torii, S | 1 |
| Ishihama, Y | 1 |
| Inaba, K | 1 |
| Anazawa, T | 1 |
| Nagamine, T | 3 |
| Mori, K | 2 |
| Ozasa, R | 1 |
| Okada, T | 1 |
| Nadanaka, S | 1 |
| Zyryanova, A | 1 |
| Harding, H | 1 |
| Ron, D | 1 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Lu, CH | 1 |
| Yan, YH | 1 |
| Ren, XS | 1 |
| Crivera, C | 1 |
| Sikirica, M | 1 |
| Dirani, R | 1 |
| Qian, S | 1 |
| Kazis, LE | 1 |
| Koro, CE | 1 |
| Fedder, DO | 1 |
| L'Italien, GJ | 1 |
| Weiss, SS | 1 |
| Magder, LS | 1 |
| Kreyenbuhl, J | 1 |
| Revicki, DA | 1 |
| Buchanan, RW | 1 |
| Hedenmalm, K | 1 |
| Hägg, S | 1 |
| Ståhl, M | 1 |
| Mortimer, O | 1 |
| Spigset, O | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Levinton, C | 1 |
| Robinson, K | 1 |
| McIntyre, RS | 1 |
| Gupta, S | 1 |
| Koller, EA | 2 |
| Cross, JT | 2 |
| Doraiswamy, PM | 1 |
| Schneider, BS | 1 |
| Fuller, MA | 1 |
| Shermock, KM | 1 |
| Secic, M | 1 |
| Grogg, AL | 1 |
| Clark, C | 1 |
| Burge, MR | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Cohen, D | 1 |
| Schneider, B | 1 |
| Sumiyoshi, T | 1 |
| Roy, A | 1 |
| Anil, AE | 1 |
| Jayathilake, K | 1 |
| Ertugrul, A | 1 |
| Meltzer, HY | 1 |
| Liberty, IF | 1 |
| Todder, D | 1 |
| Umansky, R | 1 |
| Harman-Boehm, I | 1 |
| Schwenkreis, P | 1 |
| Assion, HJ | 1 |
| Ollendorf, DA | 1 |
| Joyce, AT | 1 |
| Rucker, M | 1 |
| Leslie, DL | 2 |
| Rosenheck, RA | 2 |
| Citrome, L | 1 |
| Jaffe, A | 1 |
| Levine, J | 1 |
| Allingham, B | 1 |
| Robinson, J | 1 |
| Østbye, T | 1 |
| Curtis, LH | 1 |
| Masselink, LE | 1 |
| Hutchison, S | 1 |
| Wright, A | 1 |
| Dans, PE | 1 |
| Schulman, KA | 1 |
| Krishnan, RR | 1 |
| Farwell, WR | 1 |
| Stump, TE | 1 |
| Wang, J | 1 |
| Tafesse, E | 1 |
| L'Italien, G | 1 |
| Tierney, WM | 1 |
| Moisan, J | 1 |
| Grégoire, JP | 1 |
| Gaudet, M | 1 |
| Cooper, D | 1 |
| Dubois, D | 1 |
| Miller, EA | 1 |
| Lauwers, K | 2 |
| De Hert, M | 2 |
| Henderson, DC | 1 |
| Nguyen, DD | 1 |
| Copeland, PM | 1 |
| Hayden, DL | 1 |
| Borba, CP | 1 |
| Louie, PM | 1 |
| Freudenreich, O | 1 |
| Evins, AE | 1 |
| Cather, C | 1 |
| Goff, DC | 1 |
| McKee, JR | 1 |
| Bodfish, JW | 1 |
| Mahorney, SL | 1 |
| Heeth, WL | 1 |
| Ball, MP | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Posey, DJ | 1 |
| McDougle, CJ | 1 |
| Rubio, G | 1 |
| Gómez-de-la-Cámara, A | 1 |
| Ledesma, F | 1 |
| Burón, JA | 1 |
| Rodríguez-Morales, A | 1 |
| Martínez-Junquera, G | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| de Rijdt, L | 1 |
| Peuskens, J | 1 |
| Mathews, M | 1 |
| Muzina, DJ | 1 |
| Wooten, J | 1 |
| Wirshing, DA | 1 |
| Pierre, JM | 1 |
| Eyeler, J | 1 |
| Weinbach, J | 1 |
| Wirshing, WC | 1 |
| Meyer, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
10 reviews available for risperidone and Diabetes Mellitus
| Article | Year |
|---|---|
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
Diabetes mellitus associated with atypical anti-psychotic medications.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Clozap | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dose | 2004 |
Atypical antipsychotics and diabetes mellitus: an association.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Female; | 2004 |
Atypical antipsychotics and diabetes mellitus.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insul | 2004 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child | 2005 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
Atypical antipsychotics: new drugs, new challenges.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Humans; Olanzapine; Psychotic D | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine | 2007 |
30 other studies available for risperidone and Diabetes Mellitus
| Article | Year |
|---|---|
Mortality and morbidity following postoperative use of short-term, low-dose quetiapine vs risperidone in patients with diabetes: Analysis using a national inpatient database.
Topics: Antipsychotic Agents; Diabetes Mellitus; Humans; Inpatients; Morbidity; Quetiapine Fumarate; Retrosp | 2020 |
Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes.
Topics: Animals; Antipsychotic Agents; Cell Line, Tumor; Diabetes Mellitus; Endoplasmic Reticulum; Insulinom | 2020 |
Atypical diabetes mellitus caused by olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Olanzapine; Risperidone | 2021 |
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.
Topics: Animals; Antipsychotic Agents; Apoptosis; Benzodiazepines; Cell Line; Cricetinae; Diabetes Mellitus; | 2013 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus; Diabetic Ketoacidosis; Fatal Outcome; Humans; Male; | 2009 |
Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Topics: Adult; Aged; Alcoholism; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Depression; | 2011 |
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes M | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlor | 2002 |
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Follow-Up St | 2002 |
Antipsychotic drugs and diabetes.
Topics: Antipsychotic Agents; Causality; Dementia; Diabetes Mellitus; Humans; Obesity; Risperidone; Weight G | 2003 |
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2003 |
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Black People; Diabetes Mellitus; Humans; Male; Mood Disorders | 2003 |
Risperidone-associated diabetes mellitus in children.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Diabetes Mellitus; Female; Humans | 2004 |
A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Fema | 2004 |
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Fema | 2004 |
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoa | 2004 |
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Case-Control Studies; Clozapine; Demogr | 2004 |
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antidepressive Agent | 2005 |
Weight gain and new onset diabetes associated with olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Humans; Mal | 2004 |
Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Databases | 2005 |
Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Fema | 2005 |
Glucose abnormalities in a non-psychotic patient treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Diabetes Mell | 2005 |
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo | 2005 |
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Comorbidi | 2005 |
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapi | 2006 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
[Glucose abnormalities in a 14-year old patient treated with a second generation antipsychotic].
Topics: Adolescent; Antipsychotic Agents; Blood Glucose; Diabetes Mellitus; Humans; Male; Personality Disord | 2006 |
Risperidone-associated new-onset diabetes.
Topics: Antipsychotic Agents; Diabetes Mellitus; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 2001 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |